The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options to Directors

29 Sep 2021 07:00

RNS Number : 2952N
NetScientific PLC
29 September 2021
 

NetScientific plc

("NetScientific" or the "Company")

Grant of Options to Directors

London, UK - 29 September 2021 - NetScientific plc (AIM:NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces that on 28 September 2021 it granted a further 183,191 options over ordinary shares of 5p each (the "Ordinary Shares") to each of its Chief Executive Officer, Dr Ilian Iliev, and its Executive Chairman, John Clarkson, (the "New Options").

The table below summarises the New Options and the existing options over Ordinary Shares held by Dr Iliev and Mr Clarkson.

 

Director

Number of existing options held

Number of New Options granted

Total number of options held

Ilian Iliev

382,465

183,191

565,656

John Clarkson

382,465

183,191

565,656

 

The grant of the New Options represents the recommendations of the Board's Remuneration Committee, in respect of remuneration arrangements for Executive Directors following the successful £7.7m placement on 29 June 2021 (the "Fundraising"). The New Options bring the interests of Dr Iliev and Mr Clarkson to approximately 2.5 per cent. of the entire issued Ordinary Shares, being the same percentage interest of their existing options prior to the Fundraising.

 

The New Options were granted under the NetScientific Share Option Scheme, pursuant to which options over a total of 1,760,545 Ordinary Shares have now been granted, representing 8.4 per cent. of the current issued share capital of the Company. The maximum potential dilution arising from options awarded under the NetScientific Share Option Scheme remains below the upper limit of 10 per cent. under the rules of the plan.

The New Options have an exercise price of 124.0 pence per share (the "Exercise Price"), which is equal to the average of the closing market quotations for Ordinary Shares over the five dealing days prior to the date on which the New Options were granted (the latter being the minimum price that could have been set).

The New Options will vest as to one third on the date of grant, as to a further third on the first anniversary of the date of grant and as to the final third on the second anniversary of the date of grant. The New Options may not be exercised earlier than the third anniversary of the date of grant. The New Options lapse 10 years after the date of grant (if not sooner in accordance with the terms of the NetScientific Share Option Scheme rules).

The FCA notifications, made in accordance with the requirements of the UK Market Abuse Regulation, are appended below.

This announcement includes inside information as defined in Article 7 of the UK version of Market Abuse Regulation No. 596/2014 as it forms part of UK law as retained EU law as defined in, and by virtue of, the European Union (Withdrawal) Act 2018, as amended, and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations. 

###

 

For more information, please contact:

 

NetScientific

Via Walbrook PR

Ilian Iliev, CEO 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel 

+44 (0)20 7220 1666

Walbrook PR

+44 (0)20 7933 8780 or netscientific@walbrookpr.com 

Nick Rome / Nicholas Johnson / Paul McManus

 

07748 325 236 / 07884 664 686 / 07980 541 893

 

 

The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail on the grant of options to PDMRs.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 Dr Ilian Iliev

2

Reason for the notification

a)

Position/status

 CEO, NetScientific plc

b)

Initial notification/ Amendment

 Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

NetScientific plc

b)

LEI

213800N5WD46G1Y7I458

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Options over Ordinary Shares

 

ISIN for NetScientific plc Ordinary Shares: GB00BN4R5Q82

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 £1.24

 183,191 options

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

N/A

e)

Date of the transaction

28 September 2021

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 John Clarkson

2

Reason for the notification

a)

Position/status

 Executive Chairman, NetScientific plc

b)

Initial notification/ Amendment

 Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

NetScientific plc

b)

LEI

213800N5WD46G1Y7I458

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Options over Ordinary Shares

 

ISIN for NetScientific plc Ordinary Shares: GB00BN4R5Q82

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

 £1.24

 183,191 options

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

N/A

e)

Date of the transaction

28 September 2021

f)

Place of the transaction

Outside a trading venue

 

 

About NetScientific

NetScientific plc (AIM: NSCI) is an active holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally. 

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong transatlantic and growing international presence, providing attractive expansion prospects. 

NSCI uses a capital-light investment structure, utilising the power of the PLC Brand, and the Group's balance sheet to anchor future investments and achieve a multiplier effect by attracting 3rd party investment for the portfolio companies. 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013 (website: netscientific.net).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBCGDCLSDDGBI
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.